Subscribe
Sign up for timely perspectives delivered to your inbox.
Portfolio Manager
Portfolio Manager | Research Analyst
Portfolio Manager | Research Analyst
Remarkable advances in biomedical research are leading to rapid growth and volatility in the biotechnology sector. An investment strategy rooted in deep analysis spanning public and private entities and using short sales to hedge against risk could help maximize return potential.
Please follow the download link to access the full Biotech whitepaper.
DownloadPortfolio Manager
Portfolio Manager | Research Analyst
Portfolio Manager | Research Analyst
Portfolio Manager
Andy Acker is Portfolio Manager of the Healthcare and Biotech strategies at Janus Henderson Investors and leads the firm’s Health Care Sector Research Team, a position he has held since 2007. Andy was an assistant portfolio manager on the healthcare strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.
Andy received his Bachelor of Science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 28 years of financial industry experience.
Portfolio Manager | Research Analyst
Daniel Lyons is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors, a role he has held since 2018. He is also a Research Analyst on the Healthcare team since 2000 and focuses on biotechnology and life science tools sectors. Daniel started consulting for Janus in 1997 and joined the research team full time in 2000.
Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 24 years of financial industry experience.
Portfolio Manager | Research Analyst
Agustin Mohedas is a Portfolio Manager and Research Analyst on the Health Care Team at Janus Henderson Investors. He is focused primarily on the biotechnology sector. Before joining the firm as a research analyst in 2019, Agustin was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.
Agustin received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a PhD in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His PhD research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 10 years of financial industry experience.
Sign up for timely perspectives delivered to your inbox.
Choose region
Country
Language
What type of investor are you?
You are now leaving our site and entering a website not operated by or affiliated with Janus Henderson Investors. While we aim to point you to useful external websites, we cannot be responsible for their content, opinions, advice or accuracy, even if you utilise the services on the linked site to invest in our products.
The protection of your personal information on other websites is not governed by Janus Henderson Investors privacy policy and Janus Henderson Investors cannot be responsible for the privacy policies utilised on such third party sites, nor for the implementation of such policies by those third parties.
You should review the Terms and Conditions of third party websites and contact the operators of such sites if you have any queries.
You are now leaving Janus Henderson's website and will be redirected to the website of the Securities and Exchange Commission (the "SEC"). Money market funds are required to provide the SEC with a monthly electronic filing of more detailed portfolio holdings information on Form N-MFP.
Janus Henderson is not responsible for the content, accuracy or timeliness and does not make any warranties, express or implied, with regard to the information obtained from other websites. This link should not be construed as either a recommendation or offer to by or sell any securities.